When failure should be the option 英文论文文献.docVIP

Petsko BMC Biology 2010,8:61 /1741-7007/8/61 CO MMENT Open Access When failure should be the option Gregory A Petsko Give me your tired, your poor, your Phase II failures… biopharmaceuticals and the overall cost is only about a Well, OK, to be honest, I’m not sure I want your tired or your poor, and besides, third of this, in part because there are fewer failures). More than half the cost comes from the clinical trials that must be undertaken once a drug candidate has been approved for human testing. pretty well covered. But I am sure that I want your P